A. Heagerty

Glutathione S-transferase GSTM1 phenotypes and protection against cutaneous tumours

R. Strange, P. Jones, J. Alldersea, 1994, The Lancet.

Hepatocyte growth factor and c‐Met expression in pericytes: implications for atherosclerotic plaque development

A. Heagerty, Y. Sai, Y. Liu, 2007, The Journal of pathology.

Contribution of VCAF‐positive cells to neovascularization and calcification in atherosclerotic plaque development

J. Hoyland, A. Heagerty, J. Hoyland, 2007, The Journal of pathology.

Noradrenaline stimulation of the phosphoinositide system: evidence for a novel hydrophobic inositol‐containing compound in resistance arterioles

J. Ollerenshaw, J. Swales, A. Heagerty, 1988, British journal of pharmacology.

2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension

S. Priori, G. Mancia, A. Zanchetti, 2004, Heart Drug.

Multiple cutaneous basal cell carcinomas: glutathione S-transferase (GSTM1, GSTT1) and cytochrome P450 (CYP2D6, CYP1A1) polymorphisms influence tumour numbers and accrual.

C. Smith, J. Lear, A. Fryer, 1996, Carcinogenesis.

Truncal site and detoxifying enzyme polymorphisms significantly reduce time to presentation of further primary cutaneous basal cell carcinoma.

J. Lear, A. Fryer, R. Strange, 1997, Carcinogenesis.